Breaking News

CuriRx Launches CuriLytics Platform for Biotherapeutic Development

To provide CMC analytical services to support complex biotherapeutic development using high resolution mass spectrometry.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CuriRx, Inc., a CRO and product development organization, launched its new CuriLytics platform with High-Resolution Chemistry Manufacturing and Control (CMC) analytical services. Leveraging its high-resolution Orbitrap mass spectrometry instrumentation, the CuriLytics platform provides support to developers of complex biotherapeutics.   The platform aims to address the challenges characterizing very complex molecules such as, recombinant proteins, monoclonal antibodies (mAb), bispecific antibo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters